Together, this altered expression profile combined with the direct PGE2 inactivation by UGT2B17 support the notion that CLL cells with high UGT2B17 are less responsive to PGE2, thus conferring a proliferative advantage that could influence CLL disease course. Here, UGT2B17 is linked to B-cell chronic lymphocytic leukemia.